Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 23, 2026

Earnings live: Intel stock plunges, with more Big Tech earnings from Apple, Microsoft, and Tesla ahead

View original at finance.yahoo.com
Earnings live: Intel stock plunges, with more Big Tech earnings from Apple, Microsoft, and Tesla ahead The fourth quarter earnings season kicks into high gear in the week ahead, with Big Tech results from Microsoft (MSFT), Meta (META), Tesla (TSLA), and Apple (AAPL) headlining the earnings calendar…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Doesn't see any real hurdles to resuming Grasberg mine operations as planned in Q2 2026

    80% confidence
  • Seeing sales growth in categories in US and Europe, albeit at a slower pace. Consumer is choosing to be more diligent in using pantry inventory and dosing products more carefully. None of this is untypical and won't sustain. Categories will return to 3-4% growth over time.

    80% confidence
  • The continued top-line strength for the core consumer segment is still a key differentiator for McCormick

    80% confidence
  • Company has confidence in plans to deliver stronger results in second half of fiscal year. Remains committed to integrated growth strategy and opportunity to reinvent P&G as the CPG company of the future.

    80% confidence
  • Global inventories of copper on exchanges have risen in recent months during a period of sharp increases in copper prices. Most analysts project the market will be tightly balanced during 2026 with some projecting deficits and others small surpluses.

    80% confidence
  • National security business continues to see good growth and prospects, and civil business is starting to reignite. The market feels like it's at an inflection point.

    80% confidence
  • The environment across key markets is marked by volatility and continued pressure from inflation, geopolitical and trade uncertainty, threat of rising unemployment, and overall consumer confidence remains low

    80% confidence
  • The company saw improvement in demand profile across every segment of the business, with premium and loyalty as biggest drivers, and positive trends in Main Cabin

    80% confidence
  • Wall Street analysts estimate 8.2% increase in EPS for Q4 2025 for S&P 500. If that rate holds, it would represent the 10th consecutive quarter of annual earnings growth.

    80% confidence
  • Grasberg mine closure impacted copper volumes by 10% for 2025 compared to forecasts

    80% confidence
  • Our fourth quarter and full year results reflect solid top line growth and strong and stable credit performance. Years of strategic preparation and our choices to consistently invest to sustain long-term growth and returns enable our results and put us in a strong position going forward.

    80% confidence
  • While anticipated some moderation in client trading activity towards back end of year, instead saw acceleration in activity, which contributed to higher volume-related costs including performance-based compensation

    80% confidence
  • Consumers, especially low- to middle-income households, continue to make more frequent trips to the store while purchasing fewer units per trip, a trend that started early in the year and accelerated through Q4

    80% confidence
  • The K-shaped economy powers trade-down in basics but trade-up within the more discretionary Beauty sub-sector

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Earnings live: Intel stock plunges, with more Big Tech earnings from Apple, Microsoft, and Tesla ahead — Source | Via News | ViaNews Market